Yan Huang

Affiliations: 
CAS, Shenzhen 
Google:
"Yan Huang"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chen S, Wu J, Tang Q, et al. (2020) Nano-micelles based on hydroxyethyl starch-curcumin conjugates for improved stability, antioxidant and anticancer activity of curcumin. Carbohydrate Polymers. 228: 115398
Xu X, Lu Q, Huang Y, et al. (2020) Anti-NMDAR encephalitis: A single-center, longitudinal study in China. Neurology(R) Neuroimmunology & Neuroinflammation. 7
Wang X, Yin H, Guan Y, et al. (2020) Graphene Oxide Covalently Grafted Fe₂B@SiO₂ Nanoparticles for Epirubicin Loading and Releasing. Journal of Nanoscience and Nanotechnology. 20: 2104-2113
Wan J, Wang L, Huang Y, et al. (2019) Using GRGDSPC peptides to improve re-endothelialization of decellularized pancreatic scaffolds. Artificial Organs
Chen Z, Hu J, Zheng Z, et al. (2019) Location of colorectal adenomas and serrated polyps in patients under age 50. International Journal of Colorectal Disease
Kong Z, Wan X, Lu Y, et al. (2019) Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. Journal of Cellular and Molecular Medicine
Wang Z, Zuo J, Gong J, et al. (2019) Development of a multiplex PCR assay for the simultaneous and rapid detection of six pathogenic bacteria in poultry. Amb Express. 9: 185
Zhang Z, Zhao Y, Lu F, et al. (2019) Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Annals of Translational Medicine. 7: 452
Zhou H, Shen J, Zhang Y, et al. (2019) Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database. Annals of Translational Medicine. 7: 439
Zhang Z, Luo F, Zhang Y, et al. (2019) The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Communications (London, England). 39: 69
See more...